Piper Sandler Maintains Overweight on TransMedics Gr, Raises Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $170 to $180.
August 01, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on TransMedics Group and raises the price target from $170 to $180.
The raised price target and maintained Overweight rating from a reputable analyst at Piper Sandler is likely to positively impact the stock price of TransMedics Group in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100